tert-Butyl (1-(piperidin-4-yl)cyclopropyl)carbamate hydrochloride

Catalog No. :
ACBGCT493
CAS No. :
2229328-10-1
Molecular Formula :
C13H25ClN2O2
Molecular Weight :
276.81

IUPAC Name:tert-butyl (1-(piperidin-4-yl)cyclopropyl)carbamate hydrochloride

tert-Butyl (1-(piperidin-4-yl)cyclopropyl)carbamate hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$105.00Login to see priceInquiryInquiry
100mg98%$179.00Login to see priceInquiryInquiry
250mg98%$358.00Login to see priceInquiryInquiry
1g98%$954.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (1-(piperidin-4-yl)cyclopropyl)carbamate hydrochloride
IUPAC Nametert-butyl (1-(piperidin-4-yl)cyclopropyl)carbamate hydrochloride
MDL No.MFCD31690880
Molecular FormulaC13H25ClN2O2
Molecular Weight276.81
SMILESO=C(OC(C)(C)C)NC1(C2CCNCC2)CC1.[H]Cl
InChI KeyKZLGETDYTPJSNW-UHFFFAOYSA-N
SynonymCarbamic acid, N-[1-(4-piperidinyl)cyclopropyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1);tert-Butyl (1-(piperidin-4-yl)cyclopropyl)carbamate hydrochloride;tert-Butyl N-[1-(piperidin-4-yl)cyclopropyl]carbamate hydrochloride
CAS No.2229328-10-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACBGCT493 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBGCT493 route product structure diagram
    ACBGCT4932229328-10-1
Inquiry

2. ACBGCT493 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBGCT493 route product structure diagram
    ACBGCT4932229328-10-1
Inquiry

Comments (0)